REV 3164 has been evaluated in a variety of intact rodent models to reveal potential utility in the prophylactic treatment of
asthma.
REV 3164 was found a potent, orally active inhibitor of rat (
IgE) passive cutaneous anaphylaxis (PCA, ED50 = 0.9 mg/kg). By contrast, at 50-200 mg/kg p.o., it did not affect guinea-pig (
IgG1) PCA. In PCA rats, both
REV 3164, 1-36 mg/kg i.p., and the known inhibitor of mast cell mediator release,
disodium cromoglycate (DSCG), 2-54 mg/kg i.p., blocked cutaneous wheals caused by i.v.
antigen challenge but not by intradermal
serotonin or
histamine. Neither
REV 3164 (0.1-10 mg/kg i.p.) nor DSCG (2-54 mg/kg i.p.) affected
Compound 48/80-induced wheals.
REV 3164 (0.01-1 mg/kg i.v. or 10 mg/kg i.p.) abolished rat (
IgE) passive lung
anaphylaxis (PLA, ED50 = 0.05 mg/kg i.v. for inhibition of elevated airway resistance).
At 10 mg/kg i.p.,
REV 3164 did not affect active lung
anaphylaxis in guinea-pigs pharmacologically manipulated to enhance the production and action of
slow reacting substance of anaphylaxis (
SRS-A), nor did it exhibit
anticholinergic activity in the rat.
REV 3164 (100 mg/kg i.p.) did not protect conscious guinea-pigs from
histamine aerosol-induced collapse. It is concluded that
REV 3164 is an oral inhibitor of
IgE-dependent
immediate hypersensitivity in the rat with
biological activities in rats and guinea-pigs similar to DSCG.